Pratham Gupta

"Our target is to take private sector role in defence production to 50%." Defence Minister - Rajnath Singh As analyst you follow the regulators/government where their focus is, if you wanna make money! Defence is lumpy but massive tailwinds!

@arjunbpillai Sharing you a ppt on pc! Yes the sector is very strong! Across pharma generics cdmo branded innovators!

@Imprathamgupta Lovely. Proves your thesis and my thesis well. Looks like Pharma is going to be front running the show soon. Catch the leader and hold on to the ride.

Watching these few setups today closely. Like I said before, couple of Chemicals and Pharma/Healthcare coming up in my scans a lot since past 2 days. Would like to see how these are playing out. Seems like a start of momentum in these names. Spot them nice and early. We get to ride the leaders.

@arjunbpillai 😞

You gotta let your winners run. You don’t need to sell just because you’re in profit. Sell when the trend actually changes. Sell when structure breaks. Sell when the stock gives you a real reason. Not every red candle means the move is over. In a strong uptrend, most dips are just pullbacks. Hold onto your winners long enough, rather than rushing to think where and when to book your profits and run. Stocks that are winners will always give you a chance to enter and also exit. There is enough signs and opportunity to do both.

@arjunbpillai Glp

NEULANDLAB In the pharma sector. Earnings past us. I see prior strong uptrend. 21 EMA surfer. Tight consolidation and volume drying up. Priming to breakout. Looking for a breakout with good volumes.

@arjunbpillai Glp

ONESOURCE Also, in the Pharma Sector. Have been watching this for a long while now. Slow mover but building up slowly. Super long base formation. Volumes completely dried up and tightness being formed towards the right side of the pivot. A breakout with good volumes would be a nice trigger above pivot.

Laurus Labs has been included for the first time in the Dow Jones Best-in-Class Index, which recognizes companies with strong ESG and governance standards. Clients? MNCs? Credibility also reaches US. Who benefits? Proof of pudding? Disc: Invested and biased from lower levels

@arjunbpillai I 100% agree 1-2 trades with biz size and big move will generate enormous wealth! Rather that catching 5-6% 1-2 day moves try to get big moves with big size. Just need 1-2 good long term swings Which saves your headache+ lower brokerage+ low stt+ passive tracking

You don’t become extremely wealthy in the market punching in 50-60 trades a month in the name of swing trading. Everyone wants fast money from the markets. Reality is that life changing money usually comes from sitting through a big move with size. The real money is made in sitting through the trade for weeks and months. Not in over analyzing movement of price every day and taking 3-4% profit and moving to next one. Most traders don’t have a bad strategy. They just don’t have the patience to hold winners. Learn to sit on your hands when you’re right.

@arjunbpillai Crazy good bro! Good going!!

US PF update as of 10th May. As mentioned in the previous update, Space has now picked up well and outperforming. $RKLB and $LUNR are my only two positions in Space. Space theme having an allocation of 33% of PF. Memory/Semi and Software names continue to do great with amazing momentum. This theme has now taken over my portfolio. $IONQ, $CRCL, $AEVA, & $TXN with a total allocation of 27% of portfolio. $MU position has now built up to 26% position size of the portfolio here. Will start trimming down the size soon on the first sign of weakness. Due to a good concentration in the above themes of Space and Memory, portfolio has made a massive jump. Currently as of 10th May, sitting on 16% alpha on S&P 500. Today portfolio has moved another 4.5% leading up to almost 28%+ since April 2026. What a ride so far 🙌 Have not been able to get time to update any of my positions in real time. Will try and get back to updating in real time. Cheers.

@arjunbpillai Proud of you broo👊🏼❤️

US PF update as of 5th May. Space was taking a pause for a bit and now starting to pick back up again. Memory/Semis and Software names are moving really well. Portfolio is moving big back to back making new highs. it's not really sustainable. Will be sizing and managing positions from here on. Currently most positions are risk free. Space allocation has been decreased just to two big leaders. $RKLB & $LUNR. Finding more software names to be allocated in. Exploring other markets such as Taiwan and Korea for AI theme (Chipset manufacturing monopoly play) Will need a bit more time for that, but going down a rabbit hole which seems to be endless. Hence not being able to update on my positions in real time much. Trying my best. Some of the biggest movers in my PF where $DOCN , $TXN and now $MU which were all sized well. $LRCX is now making a good move with an average buy of $260. $TXN sitting at 50% $MU sitting at 52% $DOCN sitting at 81% Big day today as $MU is pushing again, feels euphoric with the way $SNDK and the likes have been moving, very strong momentum. Extended names can further get extended haha. Market is also supporting the moves here. Will try and give real time updates moving forward. Until then jumping back into the rabbit hole studying other countries. Cheers.

Voltamp is down 20% today a reminder that not every “power sector proxy” is automatically a great business. Revenue was flat, but PAT fell ~50% and EBITDA margin collapsed from ~18.6% to ~13.2% due to raw material inflation, rupee depreciation and weak cost pass through.

Laurus Labs – Concall Notes (Q4 FY26) Results Snapshot: FY26 Revenue: ₹6,813 Cr (+23% YoY) Q4 Revenue: ₹1,812 Cr (+5% YoY) Gross Margins: ~60–61% (improved due to better mix) EBITDA: ₹1,826 Cr (+64% YoY) EBITDA Margin: 26.8% (operating leverage kicking in) PAT: ₹889 Cr (+148% YoY) Q4 PAT: ₹279 Cr (+19% YoY) Growth achieved despite macro challenges, supported by strong execution and mix improvement Business Performance: 1)CDMO: -Revenue contribution increasing structurally (13% in FY19 → ~31% in FY26) Growth driven by: -Late-stage commercial API supply -Transition from development to commercialization -Multiple late-stage programs expected to commercialize from FY27 -No concentration risk, diversified pipeline across customers Bio segment growth supported by: -Diversification into higher value products -Strong pipeline visibility -Fermentation scale-up underway -Commercial stage products deliver higher EBITDA margins vs development phase Affordable Medicines (Generics): -Growth driven by ARV and oncology segments -ARV business remains stable with long-term visibility (~₹2800 Cr range) -Nov-ARV segments growing faster, improving mix Capex & Capacity Expansion: -Reactor volume crossed 8200 KL -Planned capex of ~₹3000 Cr over next 2 years Key expansions: -Large greenfield manufacturing facility to be ready by March 2027 -Peptide manufacturing capacity expected by Q2 FY27 -Fermentation capacity ramp-up in progress -KRKA JV Phase 1 nearing completion -Majority capex focused on medium and large-scale manufacturing -Capex is growth-led with demand visibility Margins & Profitability -EBITDA margins improved to ~26–27% from 24% Improvement driven by: -Gross margin expansion -Better product mix -Operating leverage -Commercial business has structurally higher profitability -Margins expected to sustain, with potential for further improvement as utilization increases Balance Sheet & Investments: -Debt/EBITDA at ~1.25x, increased due to ongoing capex cycle -Debt may increase slightly in near term due to investments -Asset turnover currently ~0.9x, expected to improve with scale-up -Strong operating cash flows supporting capex Expansion into: -Peptides (including high-growth segments like weight loss) -Biotechnology and material science -Non-pharma fermentation applications (industrial chemicals, polymers) -Strong positioning as a long-term partner for global pharma clients -API and advanced intermediate focus provides longer-term revenue visibility Management Outlook: -Growth momentum expected to continue into next year -Operating leverage expected to further play out -CDMO pipeline remains strong with multiple commercialization triggers -Non-ARV business expected to drive incremental growth -Gross margins expected to sustain at current levels or improve -Credit cycle remains stable with no visible stress in capacity utilization Disclosure: Holding and Biased Analyst - @Imprathamgupta

Link of the recordings here- superprofile.bio/course/6078add…

Aster DM Q4FY26 Results: Sales: Up 18% (to 1182cr) EBITDA: 23% (to 224cr) PAT: Up 42% (to 154cr) Had discussed this in our Hospital Sector Webinar! Massive operating leverage playing out+ Turnaround play (Q1FY27 getting merged with QCIL) which will 2X their Bed capacity.

Windlas Biotech doing a Buyback at 1000. 15% Premium to the CMP. Says a lot about the Promoter Integrity. If you can't find an opportunity to deploy money at best use. Do a buyback :) Disclosure: Invested and Biased.

@arjunbpillai @thechartist26 Added -438

TruAlt Got the idea from @thechartist26 here. IPO stock who is into ethanol blending segment. It was setting up well with a long base trendline. Right hand side of the base with some tight consolidation taking place on volumes drying up. Today gave a breakout at 9:16 am itself with 18% Rvol in first 1-2 mins. 9:30am at 45% Rvol. Volumes and price is all one needs. Now within 30 mins almost 100% Rvol. Volumes spoke for itself here showing strength.

@arjunbpillai Ouch!

You already know it. Never carry positions towards earnings. A day before exit and re-enter if you have to. Earning came out great yet 9% fall post market. It's unpredictable what can happen post Earnings Announcement. Just stay clear and save the mental bandwidth.

@arjunbpillai Lez go to Drnk!? Bills on me.

@PrathamG83 Too many rockets flying in your PF too haha, soon you might have to buy me coffee ☕️

$FSLY Fastly is now again setting up with a small base. It has undercut 50 EMA and regained the position today. Will average up my position here above the pivot point. Undercut and Rallys are very strong setups. Don't ignore them. Weak hand have been taken out and now consolidating and volumes drying up. Kept a limit order above the pivot line.

@arjunbpillai Doing at CMP rest all have rocketed this hasnt yet i feel can go long

@PrathamG83 Good price action going on currently. Fundamentals is good and in the space of Edge cloud and AI infra which is doing well and showing good growth.